FDA approval of the selective HIF2α inhibitor belzutifan for advanced phaeochromocytoma and paraganglioma (PPGL) is an important milestone in precision oncology. This achievement underscores the power ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback